Rajiv Gandhi Cancer Institute & Research Center

The All India Institute Of Medical Science in New Delhi recently unveiled its new AI solution that assists with the early detection of cancer. Developed with the Centre for Development of Advanced Computing, Pune under the Ministry of Electronics and Information Technology, the AI system runs on deep learning models capable of analysing complex medical data with "unprecedented accuracy and efficiency". It was trained using a data set of 500,000 radiological and histopathological images from 1,500 cases of breast and ovarian cancers, the two most common types of cancer. It has now been applied by the Department of Gynaecology to validate cases of breast and ovarian cancer. AIIMS has made the AI solution available to cancer hospitals and research centres for implementation, with deployment already made to five undisclosed district hospitals. The Neurology Department at Aster CMI Hospital has created an AI tool for screening Carpal Tunnel Syndrome (CTS). The AI diagnostic solution can identify the median nerve in ultrasound videos and detect CTS with 95% accuracy, the hospital claimed in a statement. Singapore-headquartered Qritive was recently signed by three diagnostic centres and hospitals in India to deliver AI-driven pathology management solutions. According to a press release, Metropolis Healthcare , Rajiv Gandhi Cancer Institute, and CŌRE Diagnostics will be adopting Qritive's Pantheon image management system and AI solutions as part of their respective pathology modernisation strategies. "The integration of Qritive’s AI-powered platform into our workflows signifies a revolutionary step in enhancing precision, timeliness, and personalised diagnosis," Metropolis Healthcare CEO Surendran Chemmenkottil commented. "This collaboration will strengthen our diagnostic precision, resulting in improved patient outcomes, and reaffirm our dedication to delivering excellence in clinical care. The collaboration also has the potential to lead to the development of new AI services for the diagnosis of rare diseases," said Dinesh Chauhan, CEO of CŌRE Diagnostics. "With efficient identification of concerning areas and precise grading, integrating these tools has enhanced our workflow and diagnostic precision, offering significant benefits to our practice," Dr Gurudutt Gupta, head of the Pathology Department at Rajiv Gandhi Cancer Institute Research Centre, also said about their adoption of Qritive's technology. Amrita Hospital in Faridabab announced that the head of its Radiation Oncology department has received a grant from the government to develop a robot-assisted ultrasound system for image-guided therapies and hyperthermia for cancer treatment. Explaining his project, which has received support from the Indian Council of Medical Research, Dr Bhaskar Viswanathan said, "It is a non-invasive technique that uses focused ultrasound waves and has a huge potential in cancer treatment like tumour ablation, mild hyperthermia for radiotherapy and chemotherapy, and motion management during radiation delivery." "This cutting-edge technology will allow precise localisation of lesions, enabling targeted and effective delivery of therapeutic radiation and avoiding damage to the surrounding tissue and organs," he added. Dr Viswanathan will also collaborate with the Indian Institute of Technology, Hyderabad and Eranki Labs for this three-year p roject. Ambulance service Medulance has launched what could be the first 5G-enabled medical facility offering for corporates. Launched in a corporate office in Gurgaon, city southwest of India's capital New Delhi, the Smart Medical Room features diagnostic tools, telemedicine capabilities, and real-time monitoring systems. Enabling rapid communication and data transfer, it reduces emergency response time to "under 4 minutes," the company claimed in a statement. "[W]e are not only treating basic parameters inside the medical room like CPR or Basic Life Support [but] we’re also going to provide teleconferencing with the doctor from this medical room and we will ensure that they can see the patient’s vitals remotely – this means blood pressure, sugar levels, and ECGs can be simultaneously shown to a doctor while the patient is on [their] way to a hospital," Medulance co-founder Pranav Bajaj further explained.

MUMBAI, India & SINGAPORE--( BUSINESS WIRE )-- Qritive TM , a leading provider of AI solutions for pathology labs worldwide, announces partnership with esteemed diagnostic centres and hospitals in India: Metropolis Healthcare, Rajiv Gandhi Cancer Institute and CŌRE Diagnostics. These institutions have embraced Pantheon TM image management system (IMS) and Qritive's AI products, marking them as trailblazers in adoption of artificial intelligence in pathology workflows. The incorporation of Qritive's AI technology into premier diagnostic centres and hospitals marks substantial advancement in modernizing pathology practices, utilizing artificial intelligence to enhance diagnostic precision, streamline operational efficiency, ultimately elevating patient care. Mr Surendran Chemmenkottil, CEO, Metropolis Healthcare , stated: “ As we embark on this transformative journey with Qritive, we are enthusiastic about immense potential it holds for advancing our capabilities in pathology. The integration of Qritive's AI-powered platform into our workflows signifies revolutionary step in enhancing precision, timeliness, & personalized diagnosis. This collaboration reinforces our commitment to setting new standard in cancer care, particularly in supporting clinicians in making effective treatment decisions for prostate cancer detection .” “ Qritive is proud to have opportunity to work alongside such forward-looking healthcare institutions, seizing power of AI to improve patient outcomes and concurrently enhance life of their pathologists. Our team is eager to showcase how deep tech will support clinicians and contribute to “closing the gap” in cancer care, meeting aspirations of World Cancer Day of February 4 th . ” said Bruno Occhipinti, CEO, Qritive. “ We're thrilled to partner with Qritive, integrating their advanced AI solutions into our pathology workflow at CŌRE Diagnostics. This collaboration will strengthen our diagnostic precision, resulting in improved patient outcomes, reaffirm our dedication to delivering excellence in clinical care. The collaboration also has potential to lead to development of new AI services for the diagnosis of rare disease s." said Mr Dinesh Chauhan, CEO, CŌRE Diagnostics. Qritive's AI platform revolutionizes pathology workflows, with clinical studies showing up to 90% faster diagnoses and 80% less discordance. Improved diagnosis accuracy benefits cancer patient care. “ Qritive's IMS and AI modules have enhanced our pathology practice at RGCI. With efficient identification of concerning areas and precise grading, integrating these tools has enhanced our workflow & diagnostic precision, offering significant benefits to our practice. ” - Dr Gurudutt Gupta, HOD Pathology, Rajiv Gandhi Cancer Institute Research Centre.